Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
About us
People
Tobias Kanacher

Tobias Kanacher

Tobias Kanacher, Ph.D.

Senior Director, MIDD Consultant

Google scholar

Joined Pharmetheus in 2019, actively working in client projects
Expertise includes physiological based pharmacokinetic modeling (PBPK), pediatrics, and MIDD in therapeutic areas such as oncology, women's health, and cardiovascular diseases
Previously worked as Consultant Modeling and Simulation at SGS Exprimo NV, Belgium, where he provided advice and hands-on application of pharmacometric approaches to support drug development in various therapeutic areas, as Systems Pharmacology Expert at Bayer / Bayer Technology Services GmbH, Germany, PBPK Expert in Exploratory ADME at Nycomed: a Takeda Company, Germany, Laboratory Team Leader in Exploratory ADME at Altana Pharma AG / Nycomed Gmbh, Germany, and Laboratory Team and Target-Project Leader in Preclinical Research at Altana Pharma AG, Germany
Pharmacist Licensure (1999) from the University Marburg, Germany, and Ph.D. in Pharmaceutical Biochemistry (2003) from the University Tübingen, Germany

Pharmetheus affiliated publications

Coproporphyrin I PBPK model in the open systems pharmacology suite enables precise prediction of OATP 1B- mediated drug interactions through calibrated In vivo inhibition constants PBPK workflow for predicting clinical DDI risk of OATP1B1/3 inhibitors utilizing the CP-I biomarker: A case study with cyclosporine A Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025 Physiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma Predicting atorvastatin acid pharmacokinetics in a complex enzyme- and transporter-mediated drug–drug interaction network using physiologically based pharmacokinetic modeling Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions Development of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIs [2] A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol and Caffeine [1] A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Science & Services
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Whistleblower
Privacy Policy
Cookie Policy